• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于快速定量中和抗体和抗病毒药物的混合甲病毒-SARS-CoV-2 假病毒的研制。

Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.

机构信息

Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA.

Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.

出版信息

Cell Rep Methods. 2022 Mar 28;2(3):100181. doi: 10.1016/j.crmeth.2022.100181. Epub 2022 Feb 24.

DOI:10.1016/j.crmeth.2022.100181
PMID:35229082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8866097/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here, we describe the development of a hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) pseudovirion, which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and an RNA genome derived from a fast-expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants. In addition, as a proof of concept, we used Ha-CoV-2 to quantify the neutralizing antibodies from an infected and vaccinated individual and found that the one-dose vaccination with Moderna mRNA-1273 greatly increased the anti-serum titer by approximately 6-fold. The post-vaccination serum can neutralize all nine variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for the rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.

摘要

严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白（S）假型病毒常用于定量抗病毒药物和中和抗体。在这里，我们描述了一种杂交甲病毒-SARS-CoV-2（Ha-CoV-2）假病毒粒子的开发，它是一种非复制的 SARS-CoV-2 病毒样颗粒，由病毒结构蛋白（S、M、N 和 E）和源自快速表达的甲病毒载体的 RNA 基因组组成。我们验证了 Ha-CoV-2 可快速定量中和抗体、抗病毒药物和病毒变体。此外，作为概念验证，我们使用 Ha-CoV-2 来定量感染和接种疫苗个体的中和抗体，发现接种 Moderna mRNA-1273 疫苗一剂可使抗血清滴度增加约 6 倍。接种后的血清可中和所有测试的 9 种变体。这些结果表明，Ha-CoV-2 可作为快速定量 SARS-CoV-2 及其新兴变体中和抗体的强大平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/e9ab5d9dda85/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/37595a9706f3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/91f2f340ba0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/9e048b94496f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/93c2059d1706/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/e353c5b312db/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/8885b880e9c7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/e9ab5d9dda85/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/37595a9706f3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/91f2f340ba0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/9e048b94496f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/93c2059d1706/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/e353c5b312db/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/8885b880e9c7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff9b/9017198/e9ab5d9dda85/gr6.jpg

相似文献

1
Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.用于快速定量中和抗体和抗病毒药物的混合甲病毒-SARS-CoV-2 假病毒的研制。
Cell Rep Methods. 2022 Mar 28;2(3):100181. doi: 10.1016/j.crmeth.2022.100181. Epub 2022 Feb 24.
2
Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies.用于快速定量 SARS-CoV-2 变体和中和抗体的 Ha-CoV-2 假病毒的应用。
J Vis Exp. 2023 Sep 8(199). doi: 10.3791/65793.
3
Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination.利用微阵列进行抑制剂筛选，鉴定出 SARS-CoV-2 感染和接种疫苗中中和抗体对 Spike 变异体的高结合能力。
Theranostics. 2022 Feb 28;12(6):2519-2534. doi: 10.7150/thno.67038. eCollection 2022.
4
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.
5
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.感染和接种后对 SARS-CoV-2 的异源中和活性。
Front Immunol. 2022 May 30;13:888794. doi: 10.3389/fimmu.2022.888794. eCollection 2022.
6
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.针对 SARS-CoV-2 武汉-Hu-1 株及其关注变异株的中和活性的比较分析：基于假病毒的中和测定的性能评估。
Front Immunol. 2022 Sep 26;13:981693. doi: 10.3389/fimmu.2022.981693. eCollection 2022.
7
The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.刺突蛋白-ACE2 结合分析：评估疫苗效力和筛选 SARS-CoV-2 抑制剂及中和抗体的体外平台。
J Immunol Methods. 2022 Apr;503:113244. doi: 10.1016/j.jim.2022.113244. Epub 2022 Feb 23.
8
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.既往感染与疫苗接种产生针对 SARS-CoV-2 变异株的中和抗体效力。
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
9
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.快速灵活的平台，用于评估抗 SARS-CoV-2 抗体中和作用和刺突蛋白特异性抗病毒药物。
mSphere. 2021 Aug 25;6(4):e0057121. doi: 10.1128/mSphere.00571-21. Epub 2021 Jul 28.
10
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern and .一种基于双荧光的方法，用于鉴定针对 SARS-CoV-2 关切变异株和 的中和抗体。
J Virol. 2021 Oct 27;95(22):e0112621. doi: 10.1128/JVI.01126-21. Epub 2021 Sep 8.

引用本文的文献

1
Development of novel SARS-CoV-2 viral vectors.新型 SARS-CoV-2 病毒载体的开发。
Sci Rep. 2023 Aug 11;13(1):13053. doi: 10.1038/s41598-023-40370-8.
2
Impact of the SARS-CoV-2 nucleocapsid 203K/204R mutations on the inflammatory immune response in COVID-19 severity.SARS-CoV-2 核衣壳 203K/204R 突变对 COVID-19 严重程度中炎症免疫反应的影响。
Genome Med. 2023 Jul 21;15(1):54. doi: 10.1186/s13073-023-01208-0.
3
Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals.

本文引用的文献

1
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.甲磺酸卡莫司他通过 TMPRSS2 相关蛋白酶抑制 SARS-CoV-2 的激活，其代谢产物 GBPA 发挥抗病毒活性。
EBioMedicine. 2021 Mar;65:103255. doi: 10.1016/j.ebiom.2021.103255. Epub 2021 Mar 4.
2
The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein.新型冠状病毒核衣壳磷蛋白与 RNA 和膜相关的 M 蛋白形成相互排斥的凝聚物。
Nat Commun. 2021 Jan 21;12(1):502. doi: 10.1038/s41467-020-20768-y.
3
PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.
开发一种新型基孔肯雅病毒样复制子颗粒用于快速定量和筛选中和抗体及抗病毒药物。
Microbiol Spectr. 2023 Mar 1;11(2):e0485422. doi: 10.1128/spectrum.04854-22.
4
Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test.验证和建立 SARS-CoV-2 慢病毒替代中和测定法作为蚀斑减少中和试验的预筛选工具。
Microbiol Spectr. 2023 Feb 14;11(1):e0378922. doi: 10.1128/spectrum.03789-22. Epub 2023 Jan 5.
5
Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2.通过I型干扰素和化学抑制剂抑制脂肪酸合酶作为一种针对严重急性呼吸综合征冠状病毒2的广谱抗病毒策略。
Acta Pharm Sin B. 2022 Apr;12(4):1624-1635. doi: 10.1016/j.apsb.2022.02.019. Epub 2022 Feb 28.
6
Identification of the SHREK Family of Proteins as Broad-Spectrum Host Antiviral Factors.鉴定 SHREK 蛋白家族为广谱宿主抗病毒因子。
Viruses. 2021 May 4;13(5):832. doi: 10.3390/v13050832.
7
A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro.一种传统药物，呼吸排毒针剂（RDS），在体外可抑制严重急性呼吸综合征冠状病毒（SARS-CoV）、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和甲型流感病毒的感染。
Cell Biosci. 2021 May 29;11(1):100. doi: 10.1186/s13578-021-00609-1.
8
PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.PSGL-1 抑制 SARS-CoV 和 SARS-CoV-2 刺突糖蛋白掺入假病毒并损害假病毒附着和感染性。
Viruses. 2020 Dec 30;13(1):46. doi: 10.3390/v13010046.
PSGL-1 抑制 SARS-CoV 和 SARS-CoV-2 刺突糖蛋白掺入假病毒并损害假病毒附着和感染性。
Viruses. 2020 Dec 30;13(1):46. doi: 10.3390/v13010046.
4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
7
A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins.一项关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白亚细胞定位的系统和分子研究。
Signal Transduct Target Ther. 2020 Nov 17;5(1):269. doi: 10.1038/s41392-020-00372-8.
8
The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET.新型冠状病毒（SARS-CoV-2）膜蛋白的结构类似于糖转运蛋白SemiSWEET。
Pathog Immun. 2020 Oct 19;5(1):342-363. doi: 10.20411/pai.v5i1.377. eCollection 2020.
9
Coronavirus biology and replication: implications for SARS-CoV-2.冠状病毒的生物学与复制：对 SARS-CoV-2 的启示。
Nat Rev Microbiol. 2021 Mar;19(3):155-170. doi: 10.1038/s41579-020-00468-6. Epub 2020 Oct 28.
10
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.